Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of peripheral optical errors in age-related macular degeneration.

Journal of optometry·2026
Same author

Assessing Peripheral Focus in Myopes and Non-myopes: Introducing "Depth-of-refraction".

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Asymmetry between nasal and temporal refraction with accommodation in myopes and emmetropes.

Biomedical optics express·2026
Same author

Roadmap on advances in visual and physiological optics.

Journal of optics (2010)·2025
Same author

Carbon dot-based polyplexes with cell penetration peptides for gene transfection.

RSC advances·2025
Same author

Visual and Physiological Optics: introduction to the joint feature issue in <i>Biomedical Optics Express</i> and <i>Journal of the Optical Society of America A</i>.

Journal of the Optical Society of America. A, Optics, image science, and vision·2025

Related Experiment Video

Updated: Jun 22, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

A novel GalR2-specific peptide agonist.

Johan Runesson1, Indrek Saar, Linda Lundström

  • 1Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 21A, SE-10691 Stockholm, Sweden. johanr@neurochem.su.se

Neuropeptides
|May 27, 2009
PubMed
Summary

Researchers developed a novel peptide, M1145, showing high selectivity for the galanin receptor type 2 (GalR2). This discovery offers new therapeutic potential for targeting the galanin system in various physiological disorders.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
12:38

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

Related Experiment Videos

Last Updated: Jun 22, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
12:38

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • The galanin peptide family and its receptors are implicated in high-order physiological disorders.
  • Their co-localization with neuromodulators and up-regulation in pathological states highlight their significance.

Purpose of the Study:

  • To characterize a novel galanin receptor type 2 (GalR2) selective chimeric peptide, M1145.
  • To evaluate its binding affinity and functional response for potential therapeutic applications.

Main Methods:

  • Receptor binding assays were performed to determine affinity for GalR1, GalR2, and GalR3.
  • In vitro functional assays measured inositol phosphate (IP) accumulation to assess agonistic activity.

Main Results:

  • M1145 demonstrated over 90-fold higher affinity for GalR2 compared to GalR1 and 76-fold higher affinity compared to GalR3.
  • The peptide exhibited agonistic effects, increasing IP accumulation in vitro, both with and without endogenous galanin.

Conclusions:

  • The novel M1145 peptide exhibits high selectivity and agonistic activity for GalR2.
  • This subtype-specific ligand provides new insights into the galanin receptor family and opens avenues for targeting the galanin system as a drug target.